Literature DB >> 18223667

Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

S Morishima1, F Suzuki, H Yoshiki, A S Md Anisuzzaman, Z S Sathi, T Tanaka, I Muramatsu.   

Abstract

BACKGROUND AND
PURPOSE: In addition to alpha1A, alpha1B and alpha1D-adrenoceptors (ARs), putative alpha1L-ARs with a low affinity for prazosin have been proposed. The purpose of the present study was to identify the alpha1A-AR and clarify its pharmacological profile using a radioligand binding assay. EXPERIMENTAL APPROACH: Binding experiments with [3H]-silodosin and [3H]-prazosin were performed in intact tissue segments and crude membrane preparations of rat cerebral cortex. Intact tissue binding assays were also conducted in rat tail artery. KEY
RESULTS: [3H]-silodosin at subnanomolar concentrations specifically bound to intact tissue segments and membrane preparations of rat cerebral cortex at the same density (approximately 150 fmol mg(-1) total tissue protein). The binding sites in intact segments consisted of alpha1A and alpha1L-ARs that had different affinities for prazosin, while the binding sites in membranes showed an alpha1A-AR-like profile having single high affinity for prazosin. [3H]-prazosin also bound at subnanomolar concentrations to alpha1A and alpha1B-ARs but not alpha1L-ARs in cerebral cortex; the binding densities being approximately 200 and 290 fmol mg(-1) protein in the segments and the membranes, respectively. In the segments of tail artery, [3H]-silodosin only recognized alpha1A-ARs, whereas [3H]-prazosin bound to alpha1A and alpha1B-ARs. CONCLUSIONS AND IMPLICATIONS: The present study clearly reveals the presence of alpha1L-ARs as a pharmacologically distinct entity from alpha1A and alpha1B-ARs in intact tissue segments of rat cerebral cortex but not tail artery. However, the alpha1L-ARs disappeared after tissue homogenization, suggesting their decomposition and/or their pharmacological profile changes to that of alpha1A-ARs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223667      PMCID: PMC2437907          DOI: 10.1038/sj.bjp.0707679

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 2.  Quantifying receptor properties: the tissue segment binding method - a powerful tool for the pharmacome analysis of native receptors.

Authors:  Ikunobu Muramatsu; Takashi Tanaka; Fumiko Suzuki; Zhang Li; Yasuko Hiraizumi-Hiraoka; Abu Syed Md Anisuzzaman; Hatsumi Yamamoto; Takahiro Horinouchi; Shigeru Morishima
Journal:  J Pharmacol Sci       Date:  2005-08-05       Impact factor: 3.337

3.  Alpha1-adrenoceptor subtypes and two receptor systems in vascular tissues.

Authors:  I Muramatsu; S Murata; M Isaka; H L Piao; J Zhu; F Suzuki; S Miyamoto; M Oshita; Y Watanabe; T Taniguchi
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

4.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin.

Authors:  I Muramatsu; T Taniguchi; K Okada
Journal:  Jpn J Pharmacol       Date:  1998-11

Review 6.  Alpha1-adrenoceptor subtypes.

Authors:  H Zhong; K P Minneman
Journal:  Eur J Pharmacol       Date:  1999-06-30       Impact factor: 4.432

7.  Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells.

Authors:  T Taniguchi; R Inagaki; S Murata; I Akiba; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 8.  Fundamental considerations of beta-adrenoceptor subtypes in human heart failure.

Authors:  Peter Molenaar; William A Parsonage
Journal:  Trends Pharmacol Sci       Date:  2005-07       Impact factor: 14.819

9.  Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery.

Authors:  W B Stam; P H Van der Graaf; P R Saxena
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

10.  Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding.

Authors:  Shigeru Morishima; Takashi Tanaka; Hatsumi Yamamoto; Fumiko Suzuki; Hironobu Akino; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

View more
  9 in total

1.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 2.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

3.  Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.

Authors:  I Muramatsu; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; M C Rodrigo; B E Myagmar; P C Simpson
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

4.  Pharmacologically distinct phenotypes of α1B -adrenoceptors: variation in binding and functional affinities for antagonists.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Abu Syed Md Anisuzzaman; Hidenori Umada; Ryoji Hayashi; Mie Kainoh; Takayoshi Masuoka; Matomo Nishio; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 5.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate.

Authors:  T-H Su; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; J-T Cheng; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

7.  The alpha1L-adrenoceptor is an alternative phenotype of the alpha1A-adrenoceptor.

Authors:  Cp Nelson
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

8.  Expression of distinct alpha 1-adrenoceptor phenotypes in the iris of pigmented and albino rabbits.

Authors:  I Muramatsu; F Suzuki; A Nishimune; A S M Anisuzzaman; H Yoshiki; T-H Su; C-K Chang; S Morishima
Journal:  Br J Pharmacol       Date:  2009-05-12       Impact factor: 8.739

9.  Re-evaluation of nicotinic acetylcholine receptors in rat brain by a tissue-segment binding assay.

Authors:  Mao-Hsien Wang; Hatsumi Yoshiki; Abu Syed Md Anisuzzaman; Junsuke Uwada; Atsushi Nishimune; Kung-Shing Lee; Takanobu Taniguchi; Ikunobu Muramatsu
Journal:  Front Pharmacol       Date:  2011-10-19       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.